Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR AML-001 Study of Onureg

▴ Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR AML-001 Study of Onureg
Results demonstrated treatment with Onureg improved overall survival, compared to placebo, in patients with AML in first remission.

Bristol Myers Squibb today announced new results from the QUAZAR AML-001 study presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, evaluating Onureg (azacitidine tablets; CC-486), an oral hypomethylating agent, as a treatment for adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy. Results demonstrated treatment with Onureg improved overall survival (OS), the primary endpoint of the study, as well as showed clinical benefit across other key secondary endpoints, compared to placebo, in patients with AML in first remission.

A longitudinal assessment of measurable residual disease (MRD) status from QUAZAR AML-001 evaluated treatment with Onureg in patients with both MRD positive (MRD+) and MRD negative (MRD-) status at baseline. The MRD evaluable cohort comprised 463/472 randomized patients (Onureg, N=236; placebo, N=227).

  • Median OS was prolonged with Onuregcompared with placebo in patients who were either MRD+ (median 14.6 vs. 10.4 months, respectively; HR: 0.69 [95% CI: 0.51, 0.93]) or MRD- (median 30.1 vs. 24.3 months; HR: 0.81 [0.59, 1.12]) at baseline.
  • The median duration of MRD negativity was extended with Onuregvs. placebo (11.0 vs. 5.0 months, respectively; HR: 0.62 [95% CI: 0.48, 0.78]). Treatment with Onureg also resulted in a higher rate of MRD response (MRD+ to MRD-) vs. placebo: 37% vs. 19%, respectively.
  • Median relapse-free survival (RFS) was extended with Onureg for both MRD+ (7.1 vs. 2.7 months, respectively; HR: 0.58 [95% CI: 0.43, 0.78]) and MRD- patients (13.4 vs. 7.8 months; HR: 0.71 [0.52, 0.98]).
  • The MRD assay used in the QUAZAR AML-001 study is not part of the label recently approved by the U.S. Food and Drug Administration (FDA) for Onuregas a continued treatment for adult patients with AML who achieved first CR or CRi following intensive induction chemotherapy and who are not able to complete intensive curative therapy.

Results from a separate post-hoc analysis evaluated treatment with Onureg in patients from the QUAZAR AML-001 study who had a range of prior consolidation chemotherapy cycles.

  • 472 patients were randomized to Onureg (N=238) or placebo (N=234) and most patients (80%) received consolidation before study entry. Common agents used for consolidation were cytarabine, idarubicin and daunorubicin.
  • In the cohort where no prior consolidation was administered, median OS withOnureg(N=52) vs. placebo (N=42) was 23.3 vs. 10.9 months, respectively (HR: 0.55 [95% CI: 0.34, 0.89]), and median RFS was 8.4 vs. 3.9 months (0.55 [0.34, 0.88]).
  • In the cohort of patients who received one cycle of consolidation treatment, median OS was 21.0 vs. 14.3 months with Onureg(N=110) vs. placebo (N=102), respectively (HR: 0.75 [95% CI: 0.55, 1.02]), and median RFS was 10.0 vs. 4.7 months (0.72 [0.53, 0.99]).
  • In the ≥2 consolidations cohort, median OS was 28.6 months with Onureg(N=76) vs. 17.6 months with placebo (N=90) (HR: 0.75 [95% CI: 0.50, 1.11]), and median RFS was 13.0 vs. 6.1 months (0.59 [0.41, 0.87]).

“These analyses from the QUAZAR AML-001 study provide further insight into the clinical activity of Onureg and its potential role in the treatment paradigm of patients with acute myeloid leukemia in first remission following intensive chemotherapy,” said Andrew Wei, MBBS, Ph.D., QUAZAR AML-001 lead investigator, Alfred Hospital and Monash University, Melbourne, Australia. “Persistence of acute myeloid leukemia is frequently measurable after intensive chemotherapy, and these new analyses from the pivotal trial demonstrate that Onureg can improve survival in patients with or without measurable residual disease, and across a range of consolidation cycles.”

An additional post-hoc analysis showed treatment with Onureg was associated with reduced risk of hospitalization events and days in hospital, as well as estimated cost savings associated with hospitalizations, compared with placebo. Hospitalization events in the study were collected starting from informed consent signature through 28 days after the last intraperitoneal (IP) dose. Rates of hospitalization and days in hospital were adjusted for duration of Onureg and placebo exposure. 469 patients received Onureg (N=236) or placebo (N=233). In all, 108 patients (45.8%) in the Onureg arm and 118 (50.6%) in the placebo arm were hospitalized. The analysis showed that Onureg reduced exposure-related rate of hospitalization and days in hospital compared to placebo in the QUAZAR AML-001 study. Additionally, the analysis showed that extended remission periods with Onureg compared to placebo may translate into hospitalization-related cost reductions due to reduced rates of hospitalization and days in the hospital.

“New data we’re presenting for Onureg at ASH highlight its potential to improve long-term outcomes for people living with this aggressive blood cancer,” said Samit Hiravat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb. “Moreover, oral treatment options like Onureg that can be taken at home are even more important than ever before for patients.”

Tags : #LatestPharmaNewsDec8 #LatestBristolMyersSquibbNewsDec8 #TreatmentforMyeloidLuekemia

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025